Yifang polypeptide composition as well as preparation method and application thereof

Abstract

The invention discloses a Yifang polypeptide composition as well as a preparation method and application thereof, and belongs to the technical field of compositions. The beneficial formula polypeptide composition comprises a probiotic mixture, a prebiotic mixture and a polypeptide mixture. The composition capable of achieving a multi-target synergistic effect is constructed by scientifically compounding probiotics, prebiotics and various active polypeptides, so that the intestinal flora balance can be adjusted, the release of inflammatory factors can be inhibited through the biological activity of the polypeptides, the intestinal barrier function is repaired, and the intestinal health is improved. Therefore, the problems of gastrointestinal dysfunction, skin symptoms, immune disorder and the like caused by intestinal problems are fundamentally improved, and a more comprehensive and efficient solution is provided for solving complex intestinal health problems.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of compositions, and particularly relates to a Yifang polypeptide composition and a preparation method and application thereof. BACKGROUND

[0002] Due to various manifestations of the unhealthy gastrointestinal tract of modern people, such as smoking and drinking, spicy barbecue, staying up late and insomnia, beverages and desserts, fast food and snacks, unhealthy living habits, intestinal function disorder and intestinal flora imbalance are caused. Flora disorder leads to a decrease in short-chain fatty acids (SCF), an increase in lipopolysaccharide (LPS), a destruction of the intestinal barrier, and the production of inflammatory factors, thereby activating systemic inflammatory diseases. Failure of the digestive system can cause abdominal distension and abdominal pain, acid reflux and heartburn, nausea and vomiting, loss of appetite, indigestion, alternating constipation and diarrhea, halitosis and body odor, acne and comedones, dry skin, eczema and allergies, decreased immunity, easy to catch a cold, infection, anxiety, depression, irritability, insomnia, dreaminess, and decreased sleep quality, affecting the mental state.

[0003] Due to the wide variety of the above intestinal problems, there are many oral prebiotic products on the market, mainly focusing on single strains of probiotics and prebiotics combined with single products, and objectively focusing on the activation and synergistic effect of intestinal probiotics. However, the comprehensive conditioning effect on systemic inflammatory response and multiple system symptoms caused by intestinal flora imbalance is limited, and most products still have optimization space in terms of probiotic survival rate, synergistic mechanism of prebiotics and polypeptide components. SUMMARY

[0004] The purpose of the present application is to provide a Yifang polypeptide composition and a preparation method and application thereof, by scientifically compounding probiotics, prebiotics and various active polypeptides, aiming to construct a composition capable of multi-target synergistic effect, which can not only regulate intestinal flora balance, but also inhibit the release of inflammatory factors and repair intestinal barrier function through the biological activity of polypeptides, thereby fundamentally improving gastrointestinal function disorder, skin symptoms and immune imbalance caused by intestinal problems, and providing a more comprehensive and efficient solution to complex intestinal health problems of modern people.

[0005] The purpose of the present application can be achieved by the following technical solutions: A Yifang polypeptide composition, comprising: a probiotic mixture, a prebiotic mixture and a polypeptide mixture.

[0006] As a preferred technical solution of the present application, the probiotic mixture comprises at least one of Lactobacillus paracasei GL-156, Lactobacillus paracasei LP33, Lactobacillus plantarum 550, Lactobacillus rhamnosus MP108, Lactobacillus acidophilus LA-5, Lactobacillus plantarum 360, Bifidobacterium animalis ssp. lactis BLa36, Lactobacillus fermentum CECT5716, Lactobacillus paracasei Lpc-37, Bifidobacterium longum L693, Bifidobacterium breve M-16v and Bifidobacterium lactis BI-07.

[0007] As a preferred technical solution of the present application, the prebiotic mixture comprises at least one of resistant dextrin, galactooligosaccharide, inulin, stachyose, fructooligosaccharide, isomaltooligosaccharide, soybean oligosaccharide, spirulina polysaccharide, cassia, tea polyphenol and spinach powder.

[0008] As a preferred technical solution of the present application, the polypeptide mixture comprises at least one of roxburgh rose polypeptide, oat peptide, quinoa peptide, dioscorea polypeptide, conotoxin peptide, collagen tripeptide, jellyfish peptide, collagen peptide and glutathione.

[0009] As a preferred technical solution of the present application, a preparation method of a probiotic polypeptide composition comprises the following steps: S1, respectively, each strain in the probiotic mixture is activated, expanded and cultured, concentrated, and freeze-dried under the protection of a freeze-drying protective agent to obtain a probiotic freeze-dried powder of each strain, and the probiotic freeze-dried powders are mixed to obtain the probiotic mixture; S2, the probiotic mixture, the prebiotic mixture and the polypeptide mixture are mixed to obtain the probiotic polypeptide composition.

[0010] As a preferred technical solution of the present application, the probiotic polypeptide composition is applied to regulating and improving gastrointestinal function.

[0011] As a preferred technical solution of the present application, the probiotic polypeptide composition is applied to regulating and improving constipation and diarrhea function.

[0012] As a preferred technical solution of the present application, the probiotic polypeptide composition is applied to regulating and improving acne and improving skin symptoms.

[0013] The present application has the following advantages: (1) The disclosed polypeptide composition, preparation method and application thereof improve the gastrointestinal function disorder in all directions and achieve good conditioning effect through the three-dimensional synergy of various probiotics, prebiotics and polypeptides: the stable intestinal flora structure is constructed through the synergistic effect of various probiotics, and the gastrointestinal function disorder caused by microecological imbalance is repaired; the prebiotics is added as the exclusive nutrient source of probiotics, which can not only promote the proliferation of probiotics, but also directly improve the intestinal environment and assist in conditioning the gastrointestinal function; the various polypeptides are added to promote the mucosa repair, digestive enzyme activation and gastrointestinal function regulation through the small molecule absorption characteristics.

[0014] (2) The disclosed polypeptide composition, preparation method and application thereof precisely intervene through the synergistic mechanism of various prebiotics, probiotics and polypeptides, form a synergistic system of prebiotic foundation-probiotic strengthening-polypeptide repair, amplify the conditioning effect, realize the all-round conditioning of improving defecation characteristics, stabilizing intestinal motility, repairing mucosal barrier and balancing intestinal flora, and finally achieve good therapeutic effect.

[0015] (3) The disclosed polypeptide composition, preparation method and application thereof are dominated by a polypeptide mixture, and through the synergistic effect between components, the four-dimensional synergistic effect of regulating microecology, repairing skin barrier, anti-inflammatory and antibacterial, and metabolic regulation is realized, the causes of acne and dark spots are precisely targeted, and the skin symptoms are improved, and the components form an efficient synergistic system from functional complementation to action strengthening. DETAILED DESCRIPTION

[0016] In order to further illustrate the technical means and effects adopted by the present application to achieve the predetermined object, the specific embodiments, structures, features and effects according to the present application are described in detail as follows in combination with examples.

[0017] Preparation Example 1 A preparation method of a probiotic mixture comprises the following steps: Each strain in the probiotic mixture is inoculated into sterile MRS broth medium, fully mixed, and then cultured in a 37℃ constant temperature incubator for 24h to obtain a first generation activation liquid. The above activation liquid is inoculated into MRS broth medium at 5% (v / v) and cultured at 37℃ for 24h to obtain a second generation activation liquid. The above operation is repeated three times to obtain a third generation activation liquid. The third generation culture time is 18h (the above operation must be carried out in a super-clean sterile workbench). Each probiotic liquid obtained by culturing in MRS agar medium is centrifuged, washed and concentrated. Each high-concentration bacterial liquid is freeze-dried under the protection of a freeze-drying protective agent at -65℃, a vacuum degree of 0.4Pa and a time of 25h to obtain a probiotic freeze-dried powder of each strain. The probiotic freeze-dried powders are mixed to obtain the probiotic mixture. The volume ratio of each high-concentration bacterial solution to the freeze-drying protective agent is 6:1; The freeze-drying protective agent comprises skimmed milk powder, glycerol, sodium hexametaphosphate, proline and deionized water; the mass ratio of the skimmed milk powder, glycerol, sodium hexametaphosphate, proline and deionized water is 13:10:1.55:0.85:74.6; The probiotic mixture comprises Lactobacillus paracasei GL-156, Lactobacillus paracasei LP33, Lactobacillus plantarum 550, Lactobacillus rhamnosus MP108, Lactobacillus acidophilus LA-5, Lactobacillus plantarum 360, Bifidobacterium animalis lactis subsp. lactis BLa36, Lactobacillus fermentum CECT5716, Lactobacillus paracasei Lpc-37, Bifidobacterium longum L693, Bifidobacterium breve M-16v and Bifidobacterium lactis BI-07; the live bacterial content of the prepared Lactobacillus paracasei GL-156 freeze-dried powder is 4.36×10 11 CFU / g, the live bacterial content of the Lactobacillus paracasei LP33 freeze-dried powder is 2.18×10 11 CFU / g, the live bacterial content of the Lactobacillus plantarum 550 freeze-dried powder is 0.67×10 11 CFU / g, the live bacterial content of the Lactobacillus rhamnosus MP108 freeze-dried powder is 5.12×10 11 CFU / g, the live bacterial content of the Lactobacillus acidophilus LA-5 freeze-dried powder is 2.14×10 11 CFU / g, the live bacterial content of the Lactobacillus plantarum 360 freeze-dried powder is 3.67×10 11 CFU / g, the live bacterial content of the Bifidobacterium animalis lactis subsp. lactis BLa36 freeze-dried powder is 2.78×10 11 CFU / g, the live bacterial content of the Lactobacillus fermentum CECT5716 freeze-dried powder is 3.57×10 11 CFU / g, the live bacterial content of the Lactobacillus paracasei Lpc-37 freeze-dried powder is 5.17×10 11 CFU / g, the live bacterial content of the Bifidobacterium longum L693 freeze-dried powder is 0.87×10 11 CFU / g, the live bacterial content of the Bifidobacterium breve M-16v freeze-dried powder is 2.43×10 11 CFU / g, the live bacterial content of the Bifidobacterium lactis BI-07 freeze-dried powder is 1.72×10 11 CFU / g.

[0018] MRS broth medium: weigh 10.0 g of proteose peptone, 5.0 g of sodium acetate, 20.0 g of glucose, 4.0 g of yeast extract, 0.04 g of manganese sulfate, 2.0 g of potassium phosphate dibasic, 2.0 g of diammonium hydrogen citrate, 0.2 g of magnesium sulfate, 8.0 g of beef extract, 1.0 g of Tween 80, dissolve in 1000 mL of distilled water, mix well, adjust pH to 6.5±0.2, divide into anaerobic tubes, sterilize at 118℃ for 15 min, and use for activating strains. MRS agar medium: weigh 10.0 g of proteose peptone, 5.0 g of sodium acetate, 20.0 g of glucose, 4.0 g of yeast extract, 0.04 g of manganese sulfate, 2.0 g of potassium phosphate dibasic, 2.0 g of diammonium hydrogen citrate, 0.2 g of magnesium sulfate, 8.0 g of beef extract, 14.0 g of agar powder, 1.0 g of Tween 80, dissolve in 1000 mL of distilled water, heat to boiling to dissolve completely, pour into 1000 mL of a triangular flask, seal, sterilize at 121℃ for 15 min, and use for plate counting. Preparation Example 2 A method for preparing a probiotic mixture, comprising the following steps: Each strain in the probiotic mixture was inoculated into sterile MRS broth medium, mixed well, and then cultured in a 37℃ constant temperature incubator for 24 h to obtain a first generation of activated liquid. The activated liquid was then inoculated into MRS broth medium at 5% (v / v) and cultured at 37℃ for 24 h to obtain a second generation of activated liquid. The above steps were repeated three times to obtain a third generation of activated liquid, and the culture time was 18 h. Each probiotic liquid obtained by culturing on MRS agar medium for 48 h was centrifuged, washed, and concentrated, and then each high-concentration bacterial liquid was freeze-dried under the protection of a freeze-drying protective agent at -50℃, a vacuum degree of 0.4 Pa, and a time of 30 h to obtain a probiotic freeze-dried powder of each strain. The probiotic freeze-dried powders were mixed to obtain the probiotic mixture. The volume ratio of each high-concentration bacterial liquid to the freeze-drying protective agent was 7:1. The freeze-drying protective agent comprises skimmed milk powder, glycerol, sodium hexametaphosphate, proline, and deionized water. The mass ratio of the skimmed milk powder, glycerol, sodium hexametaphosphate, proline, and deionized water is 15:11:1.70:1.05:71.25. The probiotic mixture comprises Lactobacillus paracasei GL-156, Lactobacillus paracasei LP33, Lactobacillus plantarum 550, Lactobacillus rhamnosus MP108, Lactobacillus acidophilus LA-5, Lactobacillus plantarum 360, Bifidobacterium animalis lactis BLa36, Lactobacillus fermentum CECT5716, Lactobacillus paracasei Lpc-37, Bifidobacterium longum L693, Bifidobacterium breve M-16v and Bifidobacterium lactis BI-07; Lactobacillus paracasei GL-156 lyophilized powder with a viable bacteria content of 4.78 x 1010CFU / g, Lactobacillus paracasei LP33 lyophilized powder with a viable bacteria content of 2.64 x 1010CFU / g, Lactobacillus plantarum 550 lyophilized powder with a viable bacteria content of 0.72 x 1010CFU / g, Lactobacillus rhamnosus MP108 lyophilized powder with a viable bacteria content of 5.41 x 1010CFU / g, Lactobacillus acidophilus LA-5 lyophilized powder with a viable bacteria content of 2.36 x 1010CFU / g, Lactobacillus plantarum 360 lyophilized powder with a viable bacteria content of 3.91 x 1010CFU / g, Bifidobacterium animalis lactis BLa36 lyophilized powder with a viable bacteria content of 2.96 x 1010CFU / g, Lactobacillus fermentum CECT5716 lyophilized powder with a viable bacteria content of 3.72 x 1010CFU / g, Lactobacillus paracasei Lpc-37 lyophilized powder with a viable bacteria content of 5.36 x 1010CFU / g, Bifidobacterium longum L693 lyophilized powder with a viable bacteria content of 1.02 x 1010CFU / g, Bifidobacterium breve M-16v lyophilized powder with a viable bacteria content of 2.59 x 1010CFU / g, Bifidobacterium lactis BI-07 lyophilized powder with a viable bacteria content of 1.98 x 1010CFU / g, respectively, are prepared. 11 11 11 11 11 11 11 11 11 11 11 11

[0019] Preparation Example 3 A method for preparing a probiotic mixture, comprising the steps of: ​​​​​​​​​​​​The each strain in the probiotic mixture is inoculated into sterile MRS broth culture medium, mixed thoroughly, and then cultured in a 37℃ constant temperature incubator for 24 hours to obtain a first generation of activated liquid. The activated liquid is inoculated into MRS broth culture medium at 5% (v / v) and cultured at 37℃ for 24 hours to obtain a second generation of activated liquid. The above process is repeated three times to obtain a third generation of activated liquid. The culture time of the third generation is 18 hours. The culture is performed on MRS agar medium for 48 hours. Each probiotic liquid obtained by culture is centrifuged, washed, and concentrated. Each high-concentration bacterial liquid is freeze-dried under the protection of a freeze-drying protective agent at -40℃, a vacuum degree of 0.4 Pa, and a time of 35 hours to obtain a probiotic freeze-dried powder of each strain. The probiotic freeze-dried powders are mixed to obtain the probiotic mixture. The volume ratio of the each high-concentration bacterial liquid to the freeze-drying protective agent is 8:1. The freeze-drying protective agent comprises skimmed milk powder, glycerol, sodium hexametaphosphate, proline, and deionized water. The mass ratio of the skimmed milk powder, glycerol, sodium hexametaphosphate, proline, and deionized water is 18:12:1.85:1.25:66.9. The probiotic mixture comprises Lactobacillus paracasei GL-156, Lactobacillus paracasei LP33, Lactobacillus plantarum 550, Lactobacillus rhamnosus MP108, Lactobacillus acidophilus LA-5, Lactobacillus plantarum 360, Bifidobacterium animalis lactis BLa36, Lactobacillus fermentum CECT5716, Lactobacillus paracasei Lpc-37, Bifidobacterium longum L693, Bifidobacterium breve M-16v, and Bifidobacterium lactis BI-07. The live bacterial content of the Lactobacillus paracasei GL-156 freeze-dried powder prepared separately is 4.64×10 11 CFU / g, the live bacterial content of the Lactobacillus paracasei LP33 freeze-dried powder is 2.53×10 11 CFU / g, the live bacterial content of the Lactobacillus plantarum 550 freeze-dried powder is 0.68×10 11 CFU / g, the live bacterial content of the Lactobacillus rhamnosus MP108 freeze-dried powder is 5.32×10 11 CFU / g, the live bacterial content of the Lactobacillus acidophilus LA-5 freeze-dried powder is 2.27×10 11 CFU / g, the live bacterial content of the Lactobacillus plantarum 360 freeze-dried powder is 3.75×10 11 CFU / g, the live bacterial content of the Bifidobacterium animalis lactis BLa36 freeze-dried powder is 2.81×10 11 CFU / g, the live bacterial content of the Lactobacillus fermentum CECT5716 freeze-dried powder is 3.59×10 11 CFU / g, the live bacterial content of the Lactobacillus paracasei Lpc-37 freeze-dried powder is 5.24×10 11 CFU / g, the live bacterial content of the Bifidobacterium longum L693 freeze-dried powder is 0.98×1011 CFU / g, viable bacteria content of Bifidobacterium breve M-16v lyophilized powder: 2.41 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Bifidobacterium lactis BI-07 lyophilized powder is 1.83×10⁻⁶. 11 CFU / g.

[0020] Comparative Example 1 Compared with Preparation Example 2, the difference lies in that the lyophilization protectant includes glycerol, sodium hexametaphosphate, proline, and deionized water; the mass ratio of glycerol, sodium hexametaphosphate, proline, and deionized water is 11:1.70:1.05:86.25; and the viable bacteria content of the Lactobacillus paracasei GL-156 lyophilized powder prepared is 3.78 × 10⁻⁶. 11 CFU / g, viable bacteria content of Lactobacillus paracasei LP33 lyophilized powder: 1.94 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content in 550 lyophilized Lactobacillus plantarum powder: 0.24 × 10⁻⁶ CFU / g 11 The live bacteria content of *Lactobacillus rhamnosus* MP108 lyophilized powder was 4.36 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus acidophilus LA-5 lyophilized powder is 1.78×10⁻⁶. 11 CFU / g, viable bacteria content in Lactobacillus plantarum 360 freeze-dried powder is 2.98×10⁻⁶. 11 The live bacteria content of the freeze-dried Bifidobacterium animalis subsp. lactis BLa36 was 2.05 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus fermentum CECT5716 lyophilized powder: 2.96 × 10⁻⁶ 11 CFU / g, viable bacteria content of Lactobacillus paracasei Lpc-37 lyophilized powder: 4.58 × 10⁻⁶ CFU / g 11 The live bacteria content of Bifidobacterium longum L693 lyophilized powder is 0.25×10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Bifidobacterium breve M-16v lyophilized powder is 1.89×10⁻⁶. 11 CFU / g, viable bacteria content of Bifidobacterium lactis BI-07 lyophilized powder is 1.03×10⁻⁶. 11 CFU / g.

[0021] Comparative Example 2 Compared with Preparation Example 2, the difference lies in that the freeze-drying protectant includes skim milk powder, sodium hexametaphosphate, proline, and deionized water; the mass ratio of skim milk powder, sodium hexametaphosphate, proline, and deionized water is 15:1.70:1.05:82.25; and the viable bacteria content of the Lactobacillus paracasei GL-156 freeze-dried powder prepared separately is 4.15 × 10⁻⁶. 11 CFU / g, viable bacteria content of Lactobacillus paracasei LP33 lyophilized powder: 2.01 × 10⁻⁶ CFU / g 11CFU / g, viable bacteria content in 550 lyophilized Lactobacillus plantarum powder: 0.54 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Lactobacillus rhamnosus MP108 lyophilized powder: 5.01 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Lactobacillus acidophilus LA-5 lyophilized powder: 1.98 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content in Lactobacillus plantarum 360 freeze-dried powder is 3.45×10⁻⁶. 11 The live bacteria content of the freeze-dried Bifidobacterium animalis subsp. lactis BLa36 was 2.63 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus fermentum CECT5716 lyophilized powder: 3.36 × 10⁻⁶ 11 CFU / g, viable bacteria content of Lactobacillus paracasei Lpc-37 lyophilized powder: 5.02 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Bifidobacterium longum L693 lyophilized powder is 0.65×10⁻⁶. 11 CFU / g, viable bacteria content of Bifidobacterium breve M-16v lyophilized powder: 2.27 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Bifidobacterium lactis BI-07 lyophilized powder is 1.61×10⁻⁶. 11 CFU / g.

[0022] Comparative Example 3 Compared with Preparation Example 2, the difference lies in that the freeze-drying protectant includes skim milk powder, glycerol, proline, and deionized water; the mass ratio of skim milk powder, glycerol, proline, and deionized water is 15:11:1.05:72.95; and the viable bacteria content of the resulting Lactobacillus paracasei GL-156 freeze-dried powder is 4.29 × 10⁻⁶. 11 CFU / g, viable bacteria content of Lactobacillus paracasei LP33 lyophilized powder: 2.11 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content in 550 lyophilized Lactobacillus plantarum powder: 0.59 × 10⁻⁶ CFU / g 11 The live bacteria content of the freeze-dried Lactobacillus rhamnosus MP108 powder was 5.06 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus acidophilus LA-5 lyophilized powder: 2.03 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Lactobacillus plantarum 360 freeze-dried powder is 3.54×10⁻⁶. 11 The live bacteria content of the freeze-dried Bifidobacterium animalis subsp. lactis BLa36 was 2.64 × 10⁻⁶ CFU / g. 11 The live bacteria content of Lactobacillus fermentum CECT5716 lyophilized powder is 3.49 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus paracasei Lpc-37 lyophilized powder: 5.10 × 10⁻⁶ CFU / g 11The live bacteria content of the lyophilized Bifidobacterium longum L693 was 0.78 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Bifidobacterium breve M-16v lyophilized powder: 2.32 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content of Bifidobacterium lactis BI-07 lyophilized powder is 1.61×10⁻⁶. 11 CFU / g.

[0023] Comparative Example 4 Compared with Preparation Example 2, the difference lies in that the freeze-drying protectant includes skim milk powder, glycerol, sodium hexametaphosphate, and deionized water; the mass ratio of skim milk powder, glycerol, sodium hexametaphosphate, and deionized water is 15:11:1.70:72.3; and the viable bacteria content of the Lactobacillus paracasei GL-156 freeze-dried powder prepared is 4.30 × 10⁻⁶. 11 CFU / g, viable bacteria content of Lactobacillus paracasei LP33 lyophilized powder: 2.08 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content in 550 lyophilized Lactobacillus plantarum powder: 0.61 × 10⁻⁶ CFU / g 11 The live bacteria content of *Lactobacillus rhamnosus* MP108 lyophilized powder is 5.08 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus acidophilus LA-5 lyophilized powder: 2.09 × 10⁻⁶ CFU / g 11 CFU / g, viable bacteria content in Lactobacillus plantarum 360 freeze-dried powder is 3.57×10⁻⁶. 11 The live bacteria content of the freeze-dried Bifidobacterium animalis subsp. lactis BLa36 was 2.59 × 10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Lactobacillus fermentum CECT5716 lyophilized powder: 3.43 × 10⁻⁶ 11 CFU / g, viable bacteria content of Lactobacillus paracasei Lpc-37 lyophilized powder: 5.08 × 10⁻⁶ CFU / g 11 The live bacteria content of Bifidobacterium longum L693 lyophilized powder is 0.71×10⁻⁶ CFU / g. 11 CFU / g, viable bacteria content of Bifidobacterium breve M-16v lyophilized powder is 2.34×10⁻⁶. 11 CFU / g, viable bacteria content of Bifidobacterium lactis BI-07 lyophilized powder is 1.66×10⁻⁶. 11 CFU / g.

[0024] As can be seen from Preparation Examples 1-3 and Comparative Examples 1-4, during the freeze-drying process of probiotics, the freeze-drying protectant composed of skim milk powder, glycerol, sodium hexametaphosphate, and proline provides a protective film on the surface of probiotic cells, reducing mechanical damage to cells from ice crystals and providing an energy source for the cells. Glycerol, a small-molecule permeable protectant, can enter the cells to lower the freezing point, reduce intracellular ice crystal formation, and alleviate osmotic pressure shocks during freezing. Sodium hexametaphosphate maintains the stability of the intracellular and extracellular environment of probiotics, while inhibiting protein denaturation and protecting the integrity of cell structure. Proline accumulates in the cells during drying, maintaining intracellular water balance and protecting cell membrane and enzyme activity. The synergistic effect among skim milk powder, glycerol, sodium hexametaphosphate, and proline is specifically as follows: 1) Glycerol enters the cell to lower the freezing point, reduce the formation of intracellular ice crystals, and alleviate osmotic pressure shock. Skim milk powder forms a protective film outside the cell, reducing the mechanical impact of ice crystals on the cell. The two work together to block freezing damage from inside and outside the cell. 2) Sodium hexametaphosphate maintains the osmotic pressure balance inside and outside the cell, providing a stable environment for the protective effects of glycerol and skim milk powder, and inhibiting the denaturation of probiotic proteins. The three work together to ensure the integrity of the cell structure. 3) Proline accumulates in cells, alleviating dehydration and shrinkage caused by dryness and protecting cell membranes and enzyme activity; while the nutrients provided by skim milk powder can help cells resist dryness stress, and together with proline, enhance the protective effect during the dryness stage. During the freeze-drying process of probiotics, the freeze-drying protectant composed of skim milk powder, glycerin, sodium hexametaphosphate, and proline works synergistically to provide comprehensive protection. It has a good protective effect on a variety of probiotic strains without affecting the subsequent activity and function of the probiotics, thereby increasing the activity content of each probiotic.

[0025] Application Example 1 The application of a beneficial polypeptide composition in regulating and improving gastrointestinal function includes: The probiotic mixture obtained using the preparation method of Preparation Example 2 comprises: 150 mg of lyophilized Lactobacillus paracasei GL-156, 130 mg of lyophilized Lactobacillus paracasei LP33, 150 mg of lyophilized Lactobacillus plantarum 550, 140 mg of lyophilized Lactobacillus rhamnosus MP108, 150 mg of lyophilized Lactobacillus acidophilus LA-5, 150 mg of lyophilized Lactobacillus plantarum 360, 130 mg of lyophilized Bifidobacterium animalis subsp. lactis BLa36, 130 mg of lyophilized Lactobacillus fermentum CECT5716, 150 mg of lyophilized Lactobacillus paracasei Lpc-37, 150 mg of lyophilized Bifidobacterium longum L693, 130 mg of lyophilized Bifidobacterium breve M-16v, and 150 mg of lyophilized Bifidobacterium lactis BI-07. The prebiotic mixture includes: 150 mg resistant dextrin, 160 mg galactooligosaccharide, 200 mg inulin, 160 mg stachyose, 170 mg fructooligosaccharide, and 160 mg isomaltooligosaccharide. A mixture of peptides, comprising: 150 mg of prickly pear peptide, 150 mg of conospirin peptide, and 150 mg of collagen tripeptide; Clinical trial protocol and results of Yifang polypeptide composition for the treatment of gastrointestinal dysfunction 1) Experimental subjects One hundred patients with gastrointestinal dysfunction were selected. All patients had abnormal gastrointestinal digestion and absorption functions, and were prone to abdominal distension, abdominal pain, gastrointestinal discomfort, and difficulty in passing gas after eating. They were also more likely to experience symptoms such as loss of appetite, nausea, vomiting, and burning sensation in the upper abdomen.

[0026] 2) Experimental reagents The beneficial polypeptide composition prepared in Example 1 is used.

[0027] 3) Administration method Each person takes the Yifang polypeptide composition once a day for 14 consecutive days, during which time a dedicated person will monitor and supervise the patient to take the dosage as prescribed each day.

[0028] 4) Observation indicators and scoring criteria The core scoring indicator was the degree of stomach acid and bloating. The specific scoring criteria were as follows: severe stomach acid and bloating 4 points, severe stomach acid and bloating 3 points, moderate stomach acid and bloating 2 points, mild stomach acid and bloating 1 point, and normal 0 points. The improvement of symptoms such as abdominal distension, abdominal pain, gastrointestinal discomfort, difficulty passing gas, loss of appetite, nausea, vomiting, and burning sensation in the upper abdomen was also recorded.

[0029] 5) Experimental period 14 days, calculated from the date the patient begins taking the Yifang polypeptide composition.

[0030] 6) Data collection and analysis Patients' symptoms and scores were recorded daily. After the experiment, all data were compiled, the percentage reduction in symptom scores for each patient was calculated, the treatment effect was evaluated according to the efficacy criteria, and statistical analysis was performed.

[0031] Overall therapeutic effect distribution Improvement rates of different symptoms of stomach acid and bloating: Clinically cured patients experienced complete disappearance of stomach acid and bloating symptoms; patients with significant improvement experienced significant relief of stomach acid and bloating symptoms; patients with effective results experienced improvement of stomach acid and bloating symptoms; and patients with no effect showed no significant improvement in stomach acid and bloating symptoms. Other accompanying symptoms: Abdominal distension, abdominal pain, gastrointestinal discomfort, and difficulty in passing gas have basically disappeared or been significantly reduced in patients who have recovered clinically and whose symptoms have shown significant improvement; symptoms such as loss of appetite, nausea, vomiting, and burning sensation in the upper abdomen have also been improved to varying degrees. The above symptoms in effective patients have been significantly relieved compared with those before treatment, while the symptoms in ineffective patients have not improved significantly.

[0032] The overall efficacy distribution of 100 patients after 14 days of treatment is as follows: Of the 88 cases, 88 were clinically cured; 7 showed significant improvement (7%); 3 showed improvement (3%); and 2 showed no improvement (2%). The overall effective rate (clinical cure + significant effect + effective) was 98%.

[0033] 8) Adverse reactions No significant adverse reactions were observed in any of the patients throughout the experiment, indicating that the Yifang polypeptide composition has good safety.

[0034] This program, led by a variety of probiotics and synergistically combined with prebiotics and peptides, comprehensively improves gastrointestinal dysfunction, achieving excellent conditioning results. The synergistic effect of multiple probiotics builds a stable intestinal flora structure, repairing gastrointestinal dysfunction caused by microecological imbalance. The addition of prebiotics, as a dedicated nutrient source for probiotics, not only promotes probiotic proliferation but also directly improves the intestinal environment, assisting in the conditioning of gastrointestinal function. The addition of multiple peptides, with their small molecule and easily absorbed properties, promotes mucosal repair, digestive enzyme activation, and gastrointestinal function regulation, further improving gastrointestinal function on three levels.

[0035] Application Example 2 The application of a beneficial polypeptide composition in regulating constipation and diarrhea includes: The probiotic mixture obtained by the preparation method of Preparation Example 2 includes: 150 mg of Lactobacillus paracasei GL-156 lyophilized powder, 140 mg of Lactobacillus rhamnosus MP108 lyophilized powder, 150 mg of Lactobacillus acidophilus LA-5 lyophilized powder, 130 mg of Bifidobacterium animalis subsp. lactis BLa36 lyophilized powder, 130 mg of Lactobacillus fermentum CECT5716 lyophilized powder, and 150 mg of Bifidobacterium lactis BI-07 lyophilized powder; The prebiotic mixture comprises: 200 mg resistant dextrin, 400 mg galactooligosaccharide, 500 mg inulin, 300 mg stachyose, 200 mg fructooligosaccharide, 150 mg isomaltooligosaccharide, 200 mg soybean oligosaccharide, 200 mg spirulina polysaccharide, 200 mg cassia seed, 100 mg tea polyphenols, and 300 mg spinach powder; The polypeptide mixture includes: 100 mg of prickly pear polypeptide, 100 mg of oat peptide, 100 mg of quinoa peptide, 100 mg of jellyfish peptide, and 100 mg of glutathione. Clinical trial protocol and results of Yifang polypeptide composition for the treatment of constipation and diarrhea 1) Experimental subjects One hundred patients with alternating constipation and diarrhea due to gastrointestinal dysfunction were selected. All patients had to meet the following inclusion criteria: at least two episodes per week of alternating constipation (defecation interval >48 hours, hard or lumpy stools, straining during defecation) and diarrhea (defecation frequency >3 times per day, loose or watery stools, urgency during defecation) within the past month, and other factors causing abnormal defecation, such as intestinal infection, organic lesions (e.g., intestinal polyps, tumors), and drug side effects (e.g., antibiotics, laxatives), were excluded; the age range was 18-65 years, and gender was not limited; patients voluntarily participated in the experiment and signed an informed consent form, and were able to cooperate in completing 7 days of medication and symptom recording.

[0036] 2) Experimental reagents The Yifang polypeptide composition prepared in Example 2.

[0037] 3) Administration method Each person should take the Yifang polypeptide composition once a day, dissolved in water 30 minutes after breakfast; take it for 7 consecutive days. During this period, confirm that the patient has taken the dosage as prescribed, and remind the patient to record the bowel movements of the day, and avoid taking other drugs that affect intestinal function (such as probiotic preparations, laxatives, antidiarrheal drugs) and irritating foods (such as spicy, cold, and greasy foods).

[0038] 4) Observation indicators and scoring criteria 1. Core symptom score (daily record, average of 7 days, maximum score 8 points) Constipation symptom score (0-4 points): 0 points (1 bowel movement per day, banana-shaped stool, smooth bowel movement); 1 point (1 bowel movement every 2 days, slightly dry stool, straining ≤5 minutes); 2 points (1 bowel movement every 3 days, hard stool, straining 5-10 minutes); 3 points (1 bowel movement every 4-5 days, ball-shaped stool, straining >10 minutes + assistance); 4 points (no bowel movement for >5 days, hard stool, pain + dependence on assistance); Diarrhea symptom score (0-4 points): 0 points (1 formed stool per day, no urgency); 1 point (2 soft stools per day, urgency can be tolerated for more than 10 minutes); 2 points (3 loose stools per day, urgency for 5-10 minutes, burning sensation in the anus); 3 points (4-5 watery stools per day, urgency for less than 5 minutes, anal pain); 4 points (more than 5 mucus stools per day, urgency and incontinence, redness and swelling of the anus).

[0039] 2. Accompanying symptom score (daily record, average of 7 days, maximum score 8 points) Abdominal pain (0-2 points): 0 points (none); 1 point (1-2 episodes of dull pain <10 minutes); 2 points (≥3 episodes of colic >10 minutes); Abdominal distension (0-2 points): 0 points (none); 1 point (1 instance of mild distension <1 hour); 2 points (≥2 instances of significant distension >1 hour + difficulty in passing gas); Discomfort after defecation (0-2 points): 0 points (none); 1 point (occasional feeling of pressure, relieved in <10 minutes); 2 points (frequent feeling of pressure, not relieved in >30 minutes); Impact on appetite (0-2 points): 0 points (normal); 1 point (reduction of 10%-20%); 2 points (reduction of >20% + loss of appetite).

[0040] 5) Criteria for Evaluating Therapeutic Effect The core criterion is the reduction rate of the overall symptom score after treatment (overall symptom score = constipation score + diarrhea score + accompanying symptom score, maximum score 16 points), combined with the assessment of bowel regularity stability: Clinical cure: The score is reduced by ≥95%, the core and accompanying symptoms have completely disappeared, and the defecation interval is stable and the stool is consistent. Significant effect: The score is reduced by 80%-94%, the core symptoms basically disappear (score ≤0.5 points), there are no recurrences of accompanying symptoms, and the bowel movement pattern is basically stable; Effective: 60%-79% reduction in scores, ≥50% reduction in core symptom scores, ≤1 point for accompanying symptom scores, and improvement in bowel regularity; Ineffective: Score decrease ≤59%, symptoms do not improve or worsen, bowel movement pattern remains unchanged.

[0041] 6) Treatment results Overall therapeutic effect distribution After 7 days of treatment, 54 out of 100 patients (54%) achieved clinical cure, 32 out of 100 patients (32%) showed significant improvement, 12 out of 100 patients (12%) showed improvement, and 2 out of 100 patients (2%) showed no improvement, with a total effective rate of 98%.

[0042] Improvement in core symptoms 1. Changes in symptom scores for constipation and diarrhea Before treatment: constipation score 2.7±0.8, diarrhea score 2.8±0.7, total core symptom score 5.5±1.3; After treatment: constipation score 0.09±0.18, diarrhea score 0.07±0.09, and total core symptom score 0.16±0.22.

[0043] 2. Improvement of accompanying symptoms Before treatment: Abdominal pain score 1.5±0.6, abdominal distension score 1.6±1.1, discomfort after defecation score 1.4±0.7, appetite impairment score 1.3±0.6, and total score of accompanying symptoms 5.8±1.4. After treatment: abdominal pain score 0.04±0.09, abdominal distension score 0.05±0.08, discomfort after defecation score 0.03±0.07, appetite impairment score 0.02±0.06, and total score of accompanying symptoms 0.16±0.20.

[0044] 7) Adverse reactions No significant adverse reactions were observed in any of the patients throughout the experiment, indicating that the Yifang polypeptide composition has good safety.

[0045] This treatment plan utilizes a combination of prebiotics and probiotics, along with peptides, to precisely intervene and achieve optimal therapeutic effects. The specific principles are as follows: This blend of prebiotics optimizes the gut environment and bidirectionally regulates bowel movements. For constipation, it improves intestinal motility and stool consistency, increases stool volume, softens stool, gently stimulates intestinal peristalsis, shortens intestinal transit time, and alleviates prolonged intervals between bowel movements. It also regulates intestinal osmotic pressure, promotes water retention, prevents stool from drying out, and provides lubrication for intestinal peristalsis, improving stool propulsion efficiency. For diarrhea, it repairs the intestinal barrier, reduces water loss, enhances intestinal mucosal barrier function, and reduces excessively rapid intestinal peristalsis caused by inflammation. Furthermore, it regulates intestinal flora metabolism, inhibiting the stimulation of the intestinal mucosa by toxic substances such as ammonia and indole produced by harmful bacteria, preventing spasmodic diarrhea caused by toxic irritation. By using a probiotic blend to enhance the balance of the gut microbiota and consolidate the conditioning effect of prebiotics, efficient colonization and functional performance can be achieved in the prebiotic-optimized intestinal environment, further repairing constipation and diarrhea caused by microbiota imbalance; improving probiotic colonization efficiency, providing energy for probiotics, prolonging the duration of probiotic action, relieving the urgency of defecation in patients with diarrhea, and enhancing the intestinal peristalsis in patients with constipation, thereby achieving bidirectional regulation of defecation power; through a triple mechanism of competing for nutrients, occupying mucosal attachment sites, and secreting antibacterial substances, probiotics inhibit the stimulation of the intestine by endotoxins produced by the growth of harmful bacteria, thereby reducing the alternating constipation and diarrhea caused by microbiota imbalance from the root cause; By using multiple peptides to assist in repairing functional damage and optimizing the digestive and absorptive environment, constipation and diarrhea can be improved from three levels: mucosal repair, oxidative stress relief, and digestive regulation. The three work together to form a synergistic system of prebiotic foundation, probiotic enhancement, and peptide repair, amplifying the conditioning effect to achieve comprehensive conditioning that improves bowel characteristics, stabilizes intestinal motility, repairs the mucosal barrier, and balances the intestinal flora, ultimately achieving good therapeutic results.

[0046] Application Example 3 Application of a beneficial polypeptide composition in treating acne and improving skin symptoms.

[0047] Mix the probiotic mixture, prebiotic mixture, polypeptide mixture, cyclodextrin, and deionized water, and ultrasonically stir for 30-40 minutes. Then, add the extracts of Saussurea involucrata, Impatiens balsamina, Akebia quinata, Acer rubrum root powder, and Centella asiatica in sequence, and continue stirring for 1-2 hours to obtain the Yifang polypeptide composition. The mass ratio of the probiotic mixture, prebiotic mixture, polypeptide mixture, cyclodextrin, deionized water, *Saussurea involucrata* extract, *Impatiens balsamina* extract, *Akebia quinata* extract, *Acer palmatum* root powder, and *Centella asiatica* extract is 1:1:5:8:50:0.5:0.5:0.5:0.3:0.8. The extract of *Saussurea involucrata* is derived from the ethyl acetate layer of the ethanol extract of *Saussurea involucrata*. The root powder of the hairy maple is obtained by drying and grinding the roots of the hairy maple. The probiotic mixture comprises *Lactobacillus paracasei* GL-156 lyophilized powder, *Lactobacillus rhamnosus* MP108 lyophilized powder, *Lactobacillus acidophilus* LA-5 lyophilized powder, *Bifidobacterium animalis* subsp. *lactodea* BLa36 lyophilized powder, and *Bifidobacterium lactis* BI-07 lyophilized powder; the mass ratio of the *Lactobacillus paracasei* GL-156 lyophilized powder, *Lactobacillus rhamnosus* MP108 lyophilized powder, *Lactobacillus acidophilus* LA-5 lyophilized powder, *Bifidobacterium animalis* subsp. *lactodea* BLa36 lyophilized powder, and *Bifidobacterium lactis* BI-07 lyophilized powder is 1:1.5:0.8:1.2:1.5. The prebiotic mixture includes inulin, spirulina polysaccharide, cassia seed, and tea polyphenols; the mass ratio of inulin, spirulina polysaccharide, cassia seed, and tea polyphenols is 1:0.2:0.6:0.3. The polypeptide mixture comprises prickly pear polypeptide, oat peptide, quinoa peptide, dioscorea polypeptide, conopod peptide, collagen tripeptide, jellyfish peptide, collagen peptide, and glutathione; the mass ratio of the prickly pear polypeptide, oat peptide, quinoa peptide, dioscorea polypeptide, conopod peptide, collagen tripeptide, jellyfish peptide, collagen peptide, and glutathione is 1:1:1:1:1.2:0.8:1:1:0.7; Application Comparative Example 1 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that it does not contain the extract of Sassafras salsa. The reduced amount is allocated to the extracts of Impatiens balsamina, Akebia quinata, Acer rubrum root powder and Centella asiatica, while the remaining components and amounts remain unchanged.

[0048] Application Comparative Example 2 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that it does not contain balsam extract. The reduced amount is allocated to extracts of Saussurea involucrata, Akebia quinata, Acer rubrum root powder and Centella asiatica extract in proportion to the number of parts. The remaining components and their amounts remain unchanged.

[0049] Application Comparative Example 3 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that it does not contain Akebia quinata extract. The reduced amount is allocated to the extracts of Saussurea involucrata, Impatiens balsamina, Acer pubescens root powder and Centella asiatica extract in proportion to the number of parts. The remaining components and their amounts remain unchanged.

[0050] Application Comparative Example 4 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that it does not contain Acer pubescens root powder. The reduced amount is allocated to the extracts of Saussurea involucrata, Impatiens balsamina, Akebia quinata, and Centella asiatica in proportion to the number of parts. The remaining components and their amounts remain unchanged.

[0051] Application Comparative Example 5 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that it does not contain Centella asiatica extract. The reduced amount is allocated to extracts of Saussurea involucrata, Impatiens balsamina, Akebia quinata extract, and Acer rubrum root powder in proportion to the proportions of the other components. The remaining components and their amounts remain unchanged.

[0052] Application Comparative Example 6 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that the composition does not contain a probiotic mixture. The reduced amount is allocated to the prebiotic mixture and the polypeptide mixture in proportion to the number of parts, while the remaining components and amounts remain unchanged.

[0053] Application Comparative Example 7 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that the composition does not contain a prebiotic mixture. The reduced amount is allocated to the probiotic mixture and the polypeptide mixture in proportion to the number of parts, while the remaining components and their amounts remain unchanged.

[0054] Application Comparative Example 8 This application comparative example provides a beneficial polypeptide composition. The only difference between this composition and application example 3 is that the composition does not contain a polypeptide mixture. The reduced amount is allocated to the probiotic mixture and the prebiotic mixture in proportion to the number of parts, while the remaining components and their amounts remain unchanged.

[0055] Performance testing 1) Inhibition rate of Propionibacterium acnes The Yifang polypeptide compositions prepared in Application Example 3 and Comparative Examples 1-8 were diluted with water to 2% of the composition concentration and used as test samples; phosphate buffer solution was used as control sample. Propionibacterium acnes is an anaerobic bacterium and requires cultivation in an anaerobic environment. An open anaerobic generating bag is placed in an anaerobic culture bag to create the anaerobic environment, and the oxygen content in the culture bag is observed using an anaerobic indicator. Before cultivation, the frozen strain is removed, and after freeze-thaw, it is streaked onto brain heart infusion broth medium using an inoculation loop. The medium is then incubated in an anaerobic environment at 37°C for 72 hours until distinct colonies are observed, serving as the working plate. The working plate is replaced every 20 days to ensure colony activity and stored at 4°C. To obtain Propionibacterium acnes suspension after the logarithmic growth phase, small circular colonies are picked from the working plate and placed in 1 mL of brain heart infusion broth medium. The culture is then shaken overnight in an anaerobic environment at 250 rpm and 37°C. The activated strain is then washed off with phosphate buffered saline solution to prepare a Propionibacterium acnes suspension. Take a suspension of Propionibacterium acnes and add it to each test sample and control sample, mix thoroughly, and start timing. At 10 minutes and 30 minutes of contact time, perform serial dilutions of the mixture to select 2-3 suitable dilutions. Take 0.1 mL of each dilution and place it in two sterile Petri dishes. Pour in Clostridium fortification medium, and quickly and gently rotate the Petri dishes to mix the dilutions thoroughly with the medium. After the medium solidifies, invert the Petri dishes and place them in an anaerobic environment. The bacteria were incubated at 37°C for 48 hours in an incubator. Viable bacteria counts were performed, and the inhibition rate was tested. The test results are shown in Table 1 below. Antibacterial rate = (average colony count of control sample - average colony count of test sample) / average colony count of control sample; Table 1 2) Human efficacy trials The efficacy of the Yifang polypeptide composition prepared in accordance with Case 3 and Comparative Examples 1-8 in treating acne and improving skin was evaluated. The specific evaluation method is as follows: Ninety volunteers aged 18-45 years with mild / moderate acne, accompanied by pigmentation, persistent erythema, or atrophic scars were selected and maintained a regular lifestyle during the use period. The volunteers were randomly divided into 9 groups of 10 people each; the face was divided in half, with the left side as the test area and the right side as the control area. The left side of the face was treated with the test sample, while the right side was only wiped with water. This was done continuously for 28 days. After 28 days, the total score was calculated using the evaluation items and corresponding scores shown in Table 2 below to evaluate the efficacy of treating acne and improving skin. The evaluation effect was calculated as the difference between the left side effect score and the right side effect score. The average value of each group was calculated, and the test results are shown in Table 3 below.

[0056] Table 2 Table 3 The test results above show that this solution, primarily composed of a polypeptide mixture, combined with probiotics, prebiotics, and plant extracts, achieves precise targeting of the causes of acne and pimples through the synergistic effects of its components. This is achieved through four dimensions of synergistic action: regulating the microecology, repairing the skin barrier, anti-inflammatory and antibacterial effects, and metabolic regulation. The components complement each other functionally, forming a highly efficient synergistic system. Led by peptides, this product promotes collagen synthesis and repairs damaged stratum corneum. In combination with other components, it accelerates skin healing, inhibits inflammatory signal transduction, and relieves redness and stinging. It synergizes with the anti-inflammatory effects of plant extracts and probiotics, scavenging free radicals, reducing oxidative damage, inhibiting melanin deposition, helping to fade acne scars, enhancing skin's moisture retention capacity, and strengthening the skin barrier function, providing a stable skin environment for other components to function effectively. Multiple probiotics form a dominant flora on the skin surface, directly inhibiting the growth and reproduction of harmful bacteria such as Propionibacterium acnes. Probiotic metabolites can regulate the skin's immune response and reduce inflammation. Synergistically, they enhance the anti-inflammatory effect with the anti-inflammatory components of peptides and plant extracts, improving the skin's microecological environment and creating favorable conditions for the absorption and efficacy of peptides and plant extracts. A prebiotic blend nourishes the probiotics and strengthens synergistic effects. The powder and spirulina polysaccharides provide nutrients for probiotics, promote the proliferation of beneficial bacteria, and strengthen the regulatory effect of probiotics on the skin's microecology. Tea polyphenols have antibacterial and anti-inflammatory properties, which work synergistically with probiotics and peptides to further enhance the overall antibacterial and anti-inflammatory effect. Cassia seed helps regulate skin metabolism and improve sebum secretion, and works with the barrier regulation effect of peptides to reduce pore blockage. Centella asiatica extract promotes fibroblast proliferation and accelerates skin repair, and works synergistically with the repair function of peptides to improve the healing speed of damaged skin. Extracts of Saussurea involucrata, Impatiens balsamina, Akebia quinata, and Acer rubrum root powder all contain natural anti-inflammatory and antibacterial components, which form a multi-target anti-inflammatory and antibacterial network with probiotics and peptides to enhance the inhibitory effect on acne. The natural moisturizing components of plant extracts work synergistically with peptides and prebiotics to improve the skin's water retention capacity and further strengthen the skin barrier. Furthermore, the synergistic effect of Impatiens balsamina extract and Acer pubescens root powder can directly disrupt the cell membrane structure of Propionibacterium acnes, interfere with metabolic processes, and inhibit its reproduction, avoiding the problem of narrow antibacterial spectrum or limited effect of single extracts, and effectively reducing the inflammatory triggers caused by bacteria; the terpenoids and phenolic acids in Saussurea laniceps extract can act from the upstream of inflammation, inhibiting the production and release of inflammatory factors, and blocking the initiation of the inflammatory response from the root; the anti-inflammatory components of Acer pubescens root powder focus on the midstream of inflammation, reducing the redness, swelling and pain of existing inflammation; Impatiens balsamina extract inhibits bacterial growth. The three components work synergistically to form an anti-inflammatory chain that blocks upstream inflammation, alleviates midstream inflammation, and reduces downstream triggers, thus comprehensively covering all stages of inflammation development. The triterpenoids and sterols in the Akebia quinata extract improve internal circulation, precisely regulate sebaceous gland function, reduce excessive sebum secretion, and prevent sebum from mixing with keratinocytes to form keratin plugs that clog pores, thereby reducing the basic conditions for acne formation from the root and indirectly assisting the antibacterial ingredients in exerting their effects. At the same time, balanced sebum secretion can reduce skin irritation and alleviate recurrent inflammation.

[0057] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some modifications or alterations to the above-disclosed technical content to create equivalent embodiments without departing from the scope of the present invention. Any simple modifications, equivalent changes and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. A beneficial polypeptide composition, characterized in that, include: Probiotic blends, prebiotic blends, and peptide blends.

2. The beneficial polypeptide composition according to claim 1, characterized in that, The probiotic mixture includes at least one of Lactobacillus paracasei GL-156, Lactobacillus paracasei LP33, Lactobacillus plantarum 550, Lactobacillus rhamnosus MP108, Lactobacillus acidophilus LA-5, Lactobacillus plantarum 360, Bifidobacterium animalis subsp. lactis BLa36, Lactobacillus fermentum CECT5716, Lactobacillus paracasei Lpc-37, Bifidobacterium longum L693, Bifidobacterium breve M-16v, and Bifidobacterium lactis BI-07.

3. The beneficial polypeptide composition according to claim 1, characterized in that, The prebiotic mixture includes at least one of resistant dextrin, galactooligosaccharide, inulin, stachyose, fructooligosaccharide, isomaltooligosaccharide, soybean oligosaccharide, spirulina polysaccharide, cassia seed, tea polyphenols, and spinach powder.

4. The beneficial polypeptide composition according to claim 1, characterized in that, The polypeptide mixture includes at least one of the following: prickly pear polypeptide, oat peptide, quinoa peptide, dioscorea polypeptide, conopod peptide, collagen tripeptide, jellyfish peptide, collagen peptide, and glutathione.

5. A method for preparing the Yifang polypeptide composition according to any one of claims 1-4, characterized in that, Includes the following steps: S1. Each strain in the probiotic mixture is activated and expanded through culture, concentrated, and freeze-dried under the protection of a freeze-drying protectant to obtain freeze-dried probiotic powder of each strain. The freeze-dried probiotic powders are then mixed to obtain the probiotic mixture. S2. Mix the probiotic mixture, prebiotic mixture, and polypeptide mixture to obtain the Yifang polypeptide composition.

6. The use of the beneficial polypeptide composition as described in any one of claims 1-4 in regulating and improving gastrointestinal function.

7. The use of the beneficial polypeptide composition as described in any one of claims 1-4 in regulating constipation and diarrhea.

8. The use of a beneficial polypeptide composition as described in any one of claims 1-4 in treating acne and improving skin symptoms.

Images